Bluebird bio, Inc. is a US-based pharmaceutical company with a Risk Rating Score of 29.9, placing it in the Medium Risk assessment category. Specializing in ESG-focused gene therapies for genetic diseases, the company uses its proprietary lentiviral vector (LVV) platform for research and development. Bluebird bio is dedicated to creating potentially curative treatments for severe genetic conditions, positioning itself as a leader in sustainable healthcare solutions.